drugset
drugset / Trial / NCT00369434

Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women

NCT00369434 ↗

Phase 3 Completed 450 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS SR, an extended release form of desvenlafaxine succinate, in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) associated with menopause in a population of postmenopausal women.

Timeline

Start
2006-06
Primary completion
—
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Desvenlafaxine Other / unclassified 100 mg —
Subject Desvenlafaxine Other / unclassified 150 mg —

Indications

No indication recorded.